BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know
BioMarin stock soars as the biotech firm announces a $4.8 billion acquisition of Amicus Therapeutics. The transaction could push BMRN shares even higher in 2026.
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
BioMarin to Gain Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth...
1 Oversold Stock Primed to Rebound and 2 That Underwhelm
2 Reasons to Like BMRN and 1 to Stay Skeptical
Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question